March 21st 2024
Patients with platinum-resistant or -refractory epithelial ovarian cancer treated with olaparib plus cediranib did not experience improvements in PFS and OS compared with chemotherapy.
ADC Gets FDA Fast Track Designation for Platinum-Resistant Recurrent Ovarian Cancer
January 15th 2024RC88, a mesothelin-targeting antibody-drug conjugate, was granted a fast track designation from the FDA for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.